Trevogrumab

1 Identity

Fully human monoclonal antibody, IgG4, CHO-expressed, approximately 1,320 residues across two heavy and two light chains. Not A peptide. Its presence in peptide catalogs is a category error. and as an anti-GDF8 / anti-myostatin monoclonal antibody. Sold in the research-chemical channel as "Trevogrumab 1mg".

Sequence

Recombinant antibody, sequence not reproduced. Approximately 1,320 residues total.

Molecular formula

C6374H9884N1696O2018S46 is the theoretical unglycosylated polypeptide backbone. The actual substance is N-glycosylated at the CH2 Asn297, carries C-terminal lysine clipping and N-terminal pyroglutamate, and no single molecular formula describes it.

Average mass

144,037.80 Da for the unglycosylated backbone as calculated; approximately 150 kDa empirically for the glycosylated antibody. Both figures belong on the record and the distinction between them is the point.

Monoisotopic mass

Not available and meaningless at 144 kDa — monoisotopic peaks are not resolvable for an intact IgG.

Salt / variant note

Every other myostatin- and activin-pathway biologic, none of which can be distinguished from another by intact mass, SDS-page or size-exclusion chromatography: garetosmab, apitegromab, bimagrumab, domagrozumab, landogrozumab, stamulumab. All are approximately 145 to 150 kDa IgGs. Taldefgrobep alfa sits beside that list rather than in it, and in its own format: it is not an IgG but an anti-myostatin adnectin fusion an order of magnitude smaller, and it separates from the antibodies on size-exclusion and SDS-page. ACE-083 and ACE-031 belong in the same comparison: both are Fc fusions in the same pathway and both smaller. And the folklore "myostatin inhibitor" products sold in the same category: follistatin 344, follistatin 315 and YK-11, all of which this catalog holds.

2 Class & testing panel

Form

Single article

Testing panel

Special-class panel — panel definitionThe peptide panels do not apply to an antibody

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Program evidence is current: Phase 2 COURAGE results were presented at EASD in 2025. Analytical evidence is the point of the record: an antibody cannot be certified by the methods this catalog uses for peptides, and the sellers offering it are not using antibody methods.

4 Storage & specification

Storage

Not assigned. The article is not offered.

Shelf life

Not assigned. The article is not offered.